Ras-mutant cancers are sensitive to small molecule inhibition of V-type ATPases in mice

Mutations in Ras family proteins are implicated in 33% of human cancers, but direct pharmacological inhibition of Ras mutants remains challenging. As an alternative to direct inhibition, we screened for sensitivities in Ras-mutant cells and discovered 249C as a Ras-mutant selective cytotoxic agent w...

Full description

Saved in:

Bibliographic Details
Published in:	Nature biotechnology 2022-12, Vol.40 (12), p.1834-1844
Main Authors:	Tolani, Bhairavi, Celli, Anna, Yao, Yanmin, Tan, Yong Zi, Fetter, Richard, Liem, Christina R., de Smith, Adam J., Vasanthakumar, Thamiya, Bisignano, Paola, Cotton, Adam D., Seiple, Ian B., Rubinstein, John L., Jost, Marco, Weissman, Jonathan S.
Format:	Article
Language:	English
Subjects:	631/154/555 631/67/1059/602 692/308/2778 692/699/67 Acidification Agriculture Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Autophagy Bioinformatics Biomedical and Life Sciences Biomedical Engineering/Biotechnology Biomedicine Biotechnology Cancer Cell Line, Tumor Cytotoxicity H+-transporting ATPase Humans K-Ras protein Life Sciences Mice Mutants Mutation Mutation - genetics Neoplasms - drug therapy Neoplasms - genetics Proto-Oncogene Proteins p21(ras) - genetics ras Proteins - genetics ras Proteins - metabolism Side effects Tumors Vacuolar Proton-Translocating ATPases - genetics Vacuolar Proton-Translocating ATPases - metabolism Xenografts Xenotransplantation
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!